Immune Response to Vaccines in Adults with Multiple Myeloma and Lymphoma After CAR-T Therapy

What this Trial Is About

Researchers are studying immune responses in patients with multiple myeloma and various types of non-Hodgkin lymphoma who have undergone CAR-T therapy. The study aims to understand if CAR-T therapy affects how well vaccines protect against diseases like measles, mumps, rubella, pneumococcal infections, and tetanus. This observational study evaluates antibody levels before and after CAR-T treatment to assess vaccine immunity. Participants may receive up to three doses of pneumococcal andor tetanus vaccines based on institutional revaccination policies. Blood samples are collected at multiple time points, including before CAR-T therapy, six months, and one year after vaccination, to measure changes in antibody levels and their relationship to immune cell counts. Medical records are reviewed throughout the study period. During the study, participants will have blood samples taken and their medical history monitored to track immune responses and vaccine effectiveness. The main outcome is preserved immunity up to twelve months after CAR-T cell infusion. Secondary outcomes include changes in antibody levels at baseline, six months, and one year post-vaccination. The study is expected to end in April 2027.

Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment